Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
PETHEMA Foundation
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
65High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06175702CT.gov Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL | — | Not Yet Recruiting | — | — | — |
NCT04307576CT.gov A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia | — | Recruiting | — | — | — |
NCT03878524CT.gov Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | — | Terminated | — | — | — |
NCT03007147CT.gov Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | — | Active Not Recruiting | — | — | — |
NCT03023046CT.gov Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | — | Completed | — | — | — |
NCT02881086CT.gov Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment | — | Completed | — | — | — |
NCT01312818CT.gov Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) | — | Terminated | — | — | — |
NCT00973752CT.gov Treatment of Older Adults With Acute Lymphoblastic Leukemia | — | Completed | — | — | — |
NCT02894645CT.gov Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study | — | Unknown | — | — | — |
NCT00476190CT.gov ALL Adult Consortium Trial: Adult ALL Trial | — | Completed | — | — | — |
Show 6 more trialsShow fewer
NCT00763763CT.gov Imatinib Mesylate With Vincristine and Dexamethasone in Acute Lymphoblastic Leukemias With BCR-ABL Positive | — | Completed | — | — | — |
NCT00130195CT.gov Study of Imatinib-Combined Chemotherapy for BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) | — | Completed | — | — | — |
NCT00149136CT.gov Treatment of Philadelphia-Positive Acute Lymphocytic Leukemia (Ph+ ALL) in the Elderly With Imatinib Mesylate (STI571) and Chemotherapy. | — | Unknown | — | — | — |
NCT00376467CT.gov STI 571 (GLIVEC) in the Treatment of Adult Acute Lymphoblastic Leukemia | — | Completed | — | — | — |
NCT00137111CT.gov Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia | — | Completed | — | — | — |
NCT01222013CT.gov Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+) | — | Suspended | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Acute Lymphoblastic Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Imatinib (this asset) | PETHEMA Foundation | Approved | BB · 65 |
| Gm-Csf | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | P4 | BBB |
| Peripheral Blood Stem Cells, Allogeneic, Cd34 Positive | Fred Hutchinson Cancer Center | P2/3 | BBB |
| Thioguanine Anhydrous | St. Jude Children's Research Hospital | P4 | BBB |
| Equine Atg | Instituto Nacional de Cancer, Brazil | P3 | BBB |
| Asparaginase | Centre Hospitalier Universitaire de Nice | P4 | BB |
| Mercaptopurine Anhydrous | Dana-Farber Cancer Institute | P4 | BB |
| Cyclophosphamide | Sawa Ito, MD | P4 | BB |
| Vincristine Sulfate | Children's Oncology Group | P3 | BB |
+42 more in the Acute Lymphoblastic Leukemia cohort
Other indications for Imatinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | — | P2 | BB · 71 |
| Chronic Myeloid Leukemia | — | P2 | BB · 71 |
| B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2) | — | P3 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- Gm-CsfXinhua Hospital, Shanghai Jiao Tong University School of MedicineBBB
- Peripheral Blood Stem Cells, Allogeneic, Cd34 PositiveFred Hutchinson Cancer CenterBBB
- Thioguanine AnhydrousSt. Jude Children's Research HospitalBBB
- Equine AtgInstituto Nacional de Cancer, BrazilBBB
- AsparaginaseCentre Hospitalier Universitaire de NiceBB
Citation
Floatz Terminal. Imatinib in Acute Lymphoblastic Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/imatinib-acute-lymphoblastic-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →